Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Ana Drozdowskyj, Enric Carcereny et al.|The Lancet Oncology|2012Cited by 5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung CancerRafael Rosell, Miquel Tarón, J.L. González-Larriba et al.|New England Journal of Medicine|2009Cited by 2.4k
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLCChristian Rolfo, David R. Gandara, Philip C. Mack et al.|Journal of Thoracic Oncology|2018Cited by 661
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung CancerChristian Rolfo, David R. Gandara, Philip C. Mack et al.|Journal of Thoracic Oncology|2021Cited by 642
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion studyUdai Banerji, Philippe Aftimos, Carla M.L. van Herpen et al.|The Lancet Oncology|2019Cited by 564